EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combined therapy with pirfenidone and nintedanib counteracts fibrotic silicosis in mice

Lu Bai, Jiaxin Wang, Xue Wang, Jixin Wang, Wei Zeng, Junling Pang, Tiantian Zhang, Shengxi Li, Meiyue Song iD, Yiwei Shi iD, Jing Wang iD, Chen Wang

British Journal of Pharmacology · 2025-03 · 182 (5) · 1143-1163

DOI: 10.1111/bph.17390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 15.11.2024. Verfasst von Lu Bai und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Bas…. Hauptthemen laut MEDLINE: Pyridones, Indoles, Silicosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences, National Key Research and Development Program of China Grants.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Pneumoconiosis, especially silicosis, is a prevalent occupational disease with substantial global economic implications and lacks a definitive cure. Both pneumoconiosis and idiopathic pulmonary fibrosis (IPF) are interstitial lung diseases, which share many common physiological characteristics. Because pirfenidone and nintedanib are approved to treat IPF, their potential efficacy as antifibrotic agents in advanced silicosis deserves further exploration. Thus, we aimed to evaluate the individual and combined effects of pirfenidone and nintedanib in treating advanced silicosis mice and elucidate the underlying mechanisms of their therapeutic actions via multiomics. Experimental Approach We administered monotherapy or combined therapy of pirfenidone and nintedanib, with low and high doses, in silicosis established after 6 weeks and evaluated lung function, inflammatory responses and fibrotic status. Additionally, we employed transcriptomic and metabolomic analyses to uncover the mechanisms underlying different therapeutic strategies. Key Results Both pirfenidone and nintedanib were effective in treating advanced silicosis, with superior outcomes observed in combination therapy. Transcriptomic and metabolomic analyses revealed that pirfenidone and nintedanib primarily exerted their therapeutic effects by modulating immune responses, signalling cascades and metabolic processes involving lipids, nucleotides and carbohydrates. Furthermore, we experimentally validated both monotherapy and combined therapy yielded therapeutic benefits through two common signalling pathways: steroid biosynthesis and purine metabolism. Conclusion and Implications In conclusion, pirfenidone and nintedanib, either individually or in combination, demonstrate substantial potential in advanced silicosis. Furthermore, combined therapy outperformed monotherapy, even at low doses. These therapeutic benefits are attributed to their influence on diverse signalling pathways and metabolic processes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesIndolesSilicosisAnimalsMiceDrug Therapy, CombinationMice, Inbred C57BLMaleLung

Stichwörter der Autor:innen

multiomicsnintedanibpirfenidonepulmonary fibrosissilicosis

Substanzen

pirfenidonePyridonesnintedanibIndoles

Autor:innen und Institutionen

  • State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.
  • Internal Medicine, Harbin Medical University, Harbin, China.
  • Department of Respiratory, the Second Affiliated Hospital of Harbin Medical University, Harbin, China.
  • School of Medicine, Tsinghua University, Beijing, China.
  • NHC Key Laboratory of Pneumoconiosis, Shanxi Key Laboratory of Respiratory Diseases, Department of Pulmonary and Critical Care Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.

ORCID-Profile: Meiyue Song, Yiwei Shi, Jing Wang

Förderung

  • Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
  • Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
  • National Key Research and Development Program of China Grants
  • State Key Laboratory Special Fund

Zitieren

APA

Bai, L., Wang, J., Wang, X., Wang, J., Zeng, W., Pang, J., Zhang, T., Li, S., Song, M., Shi, Y., Wang, J., & Wang, C. (2025). Combined therapy with pirfenidone and nintedanib counteracts fibrotic silicosis in mice. British Journal of Pharmacology, 182(5), 1143-1163. https://doi.org/10.1111/bph.17390

Vancouver

Bai L, Wang J, Wang X, Wang J, Zeng W, Pang J, et al. Combined therapy with pirfenidone and nintedanib counteracts fibrotic silicosis in mice. British Journal of Pharmacology. 2025;182(5):1143-1163. doi:10.1111/bph.17390

BibTeX
@article{Bai2025,
  author = {Bai, Lu and Wang, Jiaxin and Wang, Xue and Wang, Jixin and Zeng, Wei and Pang, Junling and Zhang, Tiantian and Li, Shengxi and Song, Meiyue and Shi, Yiwei and Wang, Jing and Wang, Chen},
  title = {Combined therapy with pirfenidone and nintedanib counteracts fibrotic silicosis in mice},
  journal = {British Journal of Pharmacology},
  year = {2025},
  volume = {182},
  number = {5},
  pages = {1143--1163},
  doi = {10.1111/bph.17390}
}
Kostenlos starten →